Home  »  Trending   »  We Analyzed the Future Direction of 4D Molecular T...

We Analyzed the Future Direction of 4D Molecular Therapeutics Inc. (FDMT), Here is What We Found

4D Molecular Therapeutics Inc. (NASDAQ:FDMT) went down by -1.02% from its latest closing price compared to the recent 1-year high of $24.82. The company’s stock price has collected 10.71% of gains in the last five trading sessions.

Is It Worth Investing in 4D Molecular Therapeutics Inc. (NASDAQ :FDMT) Right Now?

Opinions of the stock are interesting as 5 analysts out of 6 who provided ratings for 4D Molecular Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


The average price from analysts is $35.17, which is $11.74 above the current price. FDMT currently public float of 28.66M and currently shorts hold a 10.11% ratio of that float. Today, the average trading volume of FDMT was 490.53K shares.

FDMT’s Market Performance

FDMT stocks went up by 10.71% for the week, with a monthly jump of 210.13% and a quarterly performance of 170.78%, while its annual performance rate touched 7.34%. The volatility ratio for the week stands at 14.83% while the volatility levels for the past 30 days are set at 15.79% for 4D Molecular Therapeutics Inc. The simple moving average for the period of the last 20 days is 80.44% for FDMT stocks with a simple moving average of 119.31% for the last 200 days.

Analysts’ Opinion of FDMT

Many brokerage firms have already submitted their reports for FDMT stocks, with H.C. Wainwright repeating the rating for FDMT by listing it as a “Buy.” The predicted price for FDMT in the upcoming period, according to H.C. Wainwright is $36 based on the research report published on November 18th of the current year 2022.

Goldman, on the other hand, stated in their research note that they expect to see FDMT reach a price target of $68, previously predicting the price at $12. The rating they have provided for FDMT stocks is “Buy” according to the report published on November 15th, 2022.

SVB Leerink gave a rating of “Mkt Perform” to FDMT, setting the target price at $12 in the report published on August 12th of the current year.

FDMT Trading at 135.52% from the 50-Day Moving Average

After a stumble in the market that brought FDMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.28% of loss for the given period.

Volatility was left at 15.79%, however, over the last 30 days, the volatility rate increased by 14.83%, as shares surge +202.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +148.24% upper at present.

During the last 5 trading sessions, FDMT rose by +10.71%, which changed the moving average for the period of 200-days by +27.03% in comparison to the 20-day moving average, which settled at $13.67. In addition, 4D Molecular Therapeutics Inc. saw 6.02% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for FDMT

Current profitability levels for the company are sitting at:

  • -395.46 for the present operating margin
  • +83.26 for the gross margin

The net margin for 4D Molecular Therapeutics Inc. stands at -395.37. Equity return is now at value -36.90, with -33.40 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 15.69.